Igor Vivanco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/644909/publications.pdf

Version: 2024-02-01

28 papers	10,887 citations	304602 22 h-index	501076 28 g-index
29 all docs	29 docs citations	29 times ranked	16992 citing authors

#	Article	IF	Citations
1	The phosphatidylinositol 3-Kinaseâ€“AKT pathway in human cancer. Nature Reviews Cancer, 2002, 2, 489-501.	12.8	5,480
2	Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. New England Journal of Medicine, 2005, 353, 2012-2024.	13.9	1,376
3	Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20007-20012.	3.3	927
4	Somatic mutations of the Parkinson's diseaseâ€“associated gene PARK2 in glioblastoma and other human malignancies. Nature Genetics, 2010, 42, 77-82.	9.4	336
5	HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell, 2004, 6, 517-527.	7.7	316
6	Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. Journal of Clinical Investigation, 2009, 119, 3000-10.	3.9	308
7	Differential Sensitivity of Glioma- versus Lung Cancerâ€“Specific EGFR Mutations to EGFR Kinase Inhibitors. Cancer Discovery, 2012, 2, 458-471.	7.7	304
8	Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain. PLoS Medicine, 2006, 3, e485.	3.9	298
9	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9435-9440.	3.3	246
10	Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells. Cancer Research, 2006, 66, 7864-7869.	0.4	231
11	Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN. Cancer Cell, 2007, 11, 555-569.	7.7	214
12	Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Molecular Systems Biology, 2012, 8, 589.	3.2	168
13	Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development. Cancer Research, 2007, 67, 6083-6091.	0.4	158
14	The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6459-6464.	3.3	99
15	A kinase-independent function of AKT promotes cancer cell survival. ELife, 2014, 3, .	2.8	70
16	Identification of an Androgen-Dependent Enhancer within the Prostate Stem Cell Antigen Gene. Molecular Endocrinology, 2002, 16, 2323-2337.	3.7	54
17	Epidermal growth factor receptor inhibitors in oncology. Current Opinion in Oncology, 2010, 22, 573-578.	1.1	46
18	Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. Journal of General Virology, 2010, 91, 463-469.	1.3	41

#	Article	IF	Citations
19	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. Journal of Clinical Investigation, 2020, 130, 5875-5892.	3.9	40
20	Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. PLoS Computational Biology, 2018, 14, e1005924.	1.5	35
21	Inhibitors in AKTion: ATP-competitive vs allosteric. Biochemical Society Transactions, 2020, 48, 933-943.	1.6	27
22	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. Gut, 2021, 70, 1632-1641.	6.1	24
23	EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer. Nature Communications, 2017, 8, 2035.	5.8	23
24	A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity. British Journal of Cancer, 2020, 123, 542-555.	2.9	22
25	IQGAP1 Controls Tight Junction Formation Through Differential Regulation of Claudin Recruitment. Journal of Cell Science, 2015, 128, 853-62.	1.2	18
26	Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1517-1535.	0.4	9
27	DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF. Life Science Alliance, 2022, 5, e202101235.	1.3	8
28	14-3-3Ïƒ and p21 synergize to determine DNA damage response following Chk2 inhibition. Cell Cycle, 2009, 8, 2238-2246.	1.3	7